Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse MKT  >  CorMedix Inc.    CRMD

CORMEDIX INC.

(CRMD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
8.9(c) 8.84(c) 8.99(c) 8.84(c) 8.63(c) Last
583 013 282 302 359 199 380 936 417 671 Volume
+3.13% -0.67% +1.70% -1.67% -2.38% Change
More quotes
Financials (USD)
Sales 2020 0,23 M - -
Net income 2020 -23,5 M - -
Net cash position 2020 33,5 M - -
P/E ratio 2020 -10,5x
Yield 2020 -
Sales 2021 12,7 M - -
Net income 2021 -37,8 M - -
Net cash position 2021 76,5 M - -
P/E ratio 2021 -9,64x
Yield 2021 -
Capitalization 277 M 277 M -
EV / Sales 2020 1 074x
EV / Sales 2021 15,8x
Nbr of Employees 30
Free-Float 98,0%
More Financials
Company
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a... 
Sector
Pharmaceuticals
Calendar
03/18Earnings Release
More about the company
Notations Surperformance© of CorMedix Inc.
Trading Rating : Investor Rating :
More Ratings
All news about CORMEDIX INC.
08:58aCORMEDIX INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Ru..
AQ
08:30aCorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
GL
2020CORMEDIX INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
2020CORMEDIX INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020CORMEDIX : Announces fda decision that advisory committee meeting for new drug a..
AQ
2020SECTOR UPDATE : Losses by Health Care Stocks Adding Speed Near Wednesday Close
MT
2020CORMEDIX INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
2020SECTOR UPDATE : Health Care Stocks Struggling in Mid-Week Trade
MT
2020SECTOR UPDATE : Health Care
MT
2020CorMedix Rises After FDA Cancels Advisory Meeting for Defencath New Drug Appl..
MT
2020CORMEDIX INC. : Announces FDA Decision That Advisory Committee Meeting for New D..
AQ
2020CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New ..
GL
2020CorMedix Registers $100 Million in Securities
MT
2020CORMEDIX : 3Q Earnings Snapshot
AQ
2020CORMEDIX INC. : Results of Operations and Financial Condition, Financial Stateme..
AQ
More news
News in other languages on CORMEDIX INC.

- No features available -

More news
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | CRMD | US21900C3088 | MarketScreener
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 15,75 $
Last Close Price 8,63 $
Spread / Highest target 155%
Spread / Average Target 82,5%
Spread / Lowest Target 15,9%
EPS Revisions
Managers and Directors
NameTitle
Mohammed Khoso Baluch Chief Executive Officer & Director
Myron Lawrence Kaplan Chairman
Mathew David Chief Financial Officer & Executive Vice President
Antony E. Pfaffle Secretary & Chief Scientific Officer
John L. Armstrong EVP-Technical Operations & Head-Human Resources
Sector and Competitors
1st jan.Capitalization (M$)
CORMEDIX INC.18.98%284
MERCK KGAA1.67%75 058
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.39%27 359
KYOWA KIRIN CO., LTD.0.43%14 729
BETTA PHARMACEUTICALS CO., LTD.28.34%8 355
YUHAN CORPORATION-2.53%4 163